Table 6.
Base case: Five-year QALY and cost changes by breast cancer subtype under care disruption
| Molecular subtype | Cohort (n) | Non-disrupted care (2017–2019) | Disrupted-care (2020) | Incremental costs & QALYs (Disrupted-care vs. Non-disrupted care) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| QALYs | Cost (€) | Death % | QALYs | Cost (€) | Death % | ∆QALYs | ∆Cost (€) | ∆% Point | Additional deaths | ||
| Luminal A | Total cohort (n = 5479) | 20,987.5 | 179,522,108 | 2.80 | 20,982.7 | 180,004,052 | 2.88 | − 4.8 | 481,944 | 0.08 | 2 |
| Per patient | 3.831 | 32,765 | 3.830 | 32,853 | − 0.001 | 88 | |||||
| Luminal B | Total cohort (n = 2740) | 10,378.9 | 103,245,734 | 4.04 | 10,375.0 | 103,770,423 | 4.09 | − 4.0 | 524, 689 | 0.05 | 1 |
| Per patient | 3.788 | 37,681 | 3.786 | 37,872 | − 0.001 | 191 | |||||
| HER2 + | Total cohort (n = 609) | 2, 242.4 | 82, 155, 748 | 8.06 | 2, 240.0 | 82, 702, 749 | 8.13 | − 2.5 | 547, 000 | 0.07 | 1 |
| P,r patient | 3.682 | 134,903 | 3.678 | 135,801 | − 0.004 | 898 | |||||
| TNBC | Total cohort(n = 1319) | 4,764.4 | 319,433,158 | 10.81 | 4,754.9 | 321,072,481 | 11.01 | − 9.5 | 1,639,323 | 0.20 | 2 |
| Per patient | 3.612 | 242,178 | 3.605 | 243,421 | − 0.007 | 1,243 | |||||
| Breast cancer | Total cohort(n = 10,147) | − | -20.7 | 3,192,956 | |||||||
| Per patient | − | -0.002 | 315 | ||||||||
HER2 + Human Epidermal Growth Factor Receptor 2–positive, QALY Quality-Adjusted Life Year, TNBC Triple-Negative Breast Cancer
***bold values indicate incremental outcomes comparing disrupted care (2020) with non-disrupted care (2017–2019), representing the health and economic impact attributable to COVID-19–related breast cancer diagnosis disruption